|
Dr. Hodges joined Kémia as Chief Medical Officer and Head of Development in August 2007. He has over fifteen years of experience in pharma with Pfizer Global Research and Development working at development sites in the UK, New London CT, and La Jolla CA. He has worked in Infectious Diseases, Oncology, Respiratory, and Urogenital therapeutic areas. His career has included working on the development programs for Vfend® (voriconazole), Diflucan® (fluconazole), Zithromax® (azithromycin), Tarceva® (erlotinib) and Viagra® (sildenafil). In addition, he has worked on proof of concept clinical trials with drug candidates for HIV, Oncology, COPD, asthma, allergic rhinitis, chemotherapy induced nausea and vomiting. His most recent positions were as Executive Director, Development Team Leader in Oncology and Infectious Diseases, Pfizer Global Research and Development, La Jolla CA. Dr. Hodges received his B.Sc. in Pharmacology and Medical Degree from the University of London, UK. He trained in internal medicine in several London Medical Schools and is Member of the Royal College of Physicians, UK. | 